Digital analysis and artificial intelligence (AI) are not novel in anatomic pathology and histology, but the technology continues to evolve as it supports clinical trial enrollment as well as routine work in pathology. Paul Mesange, PhD, Principal Scientist, Histology, recently shared how Labcorp Drug Development (formerly known as Covance) has …
Meeting an Unprecedented Surge in Demand for Kit Production
Supply chain disruptions and manufacturing shortages have significantly affected the clinical trial industry, an issue exacerbated by an unprecedented demand for clinical trial kits. To help maintain business continuity, the Labcorp Central Laboratories team had to develop creative operational solutions at every step of production and quickly accelerate the launch …
Cell and gene therapy answers: Assessing the critical quality attributes, challenges and importance of CMC
Your source for answers to the complex challenges of cell and gene therapy development. Labcorp shares an introduction to CMC, key analytical methods used in assessing the Critical Quality Attributes, challenges in developing these assays and thoughts on the road ahead over the next 5-10 years. What is CMC and …
A macro investment in micro science
The science behind the development of gene- and cell-based therapies is as granular as it gets. Research at this level of precision requires the latest technology, state-of-the-art facilities and expert staff to produce optimal outcomes. In order to schedule more of your cell and gene studies and help you create …
Connecting diagnostic and drug development expertise around the world: Meet Claudine
As the drug development and diagnostic businesses of Labcorp strengthen their combined capabilities, Claudine Rigal, PharmD, Clinical Biologist, Head of Asia Pacific Laboratory Operations and Global Head of Anatomic Pathology Operations for Labcorp Drug Development, is excited about the opportunity to improve service delivery for biotech and pharma clients. We …
The role of B-cell cloning in the generation of antibody critical reagents: apoptosis-related antigen case study
B-cell cloning, a recent improvement over typical hybridoma technology, is becoming an industry standard tool for the reliable and reproducible production of monoclonal antibodies. Read on to find out how we have successfully utilized B-cell cloning to produce antibody critical reagents, for a recombinant protein, and to learn how this …
Connecting Expertise to Accelerate Lab Testing Innovations at Labcorp Central Laboratory Services
To help our clients shape the future of healthcare, Central Laboratory Services (CLS) at Labcorp Drug Development is continuously exploring new ways to enhance scientific expertise and anticipate lab testing needs. We recently spoke with Sian Estdale, PhD, Head of Scientific Affairs, Clinical Trial Testing Solutions at Labcorp, to hear …
Preclinical Oncology Renovation
According to a recent study from the American Cancer Society, over 19 million people were diagnosed with cancer in 2020. Cancer reaches every corner of the globe and touches way too many of our lives. And as the search for answers advances, all eyes are on oncology research and this …
Early Development Investments Campaign Magazine
Moving with urgency takes determination, ingenuity and passion. It also takes innovating where it matters most. The decision to invest more than $700 million in the past five years in Early Development all started with listening to you. These initiatives have spanned the entire globe with a mission to expand …
Asia Pacific Expansion
4.7 billion. That’s the approximate population of Asia as of 2021. That number represents about 59 percent of the total world population. People are living longer and with that comes the demand for improved healthcare. With the Asia Pacific region accounting for about 15 percent of the drug development pipeline …